Cellerant Therapeutics, Inc.
Records under this name other than patents Cellerant Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Cellerant Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,715,619 | Compositions and methods for treating haematological proliferative disorders of myeloid origin Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,371,390 | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,631,026 | Antibodies That Specifically Bind to TIM3 Formerly held In force · High confidence | In force | High confidence | |
| US 10,301,394 | Antibodies That Specifically Bind to TIM3 Formerly held In force · High confidence | In force | High confidence | |
| US 10,723,805 | Antibodies specific for CLL-1 Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,163,090 | Antibodies specific for CLL-1 Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,850,314 | Antibodies specific for CLL-1 Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,072,662 | Humanized anti-CLL-1 antibodies Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,359,025 | Anti-IL1-RAP antibodies Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,841,418 | Antibodies That Specifically Bind to TIM3 Formerly held Lapsed on the fee record Ended Sep 23, 2026 · High confidence | Lapsed on the fee record | Ended Sep 23, 2026 | High confidence |